Hormonal-based therapies, including estrogen regimens, selective estrogen receptor modulators, and tibolone, may be used with caution in those with a significant personal or family history of breast or uterine cancer, venous thrombosis, cardiovascular disease, and stroke. The gene discussed is ESR1; the disease is uterine cancer.